Allogene Therapeutics, Inc. (ALLO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -12.91M | -27.6M | -29.69M | -39.03M | -52.93M | -36.7M | -44.12M | -63.59M | -55.9M | -53.71M | -55.53M | -61.86M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | -254086.36% | 122061.36% | -252409.09% | -281168.18% |
| Operating CF Growth % | 75.6% | 24.79% | 32.7% | 38.62% | 5.31% | 31.67% | 20.56% | -2.8% | 16.12% | 13.51% | -16.53% | -45.44% |
| Net Income | -42.61M | -38.81M | -41.4M | -50.94M | -59.73M | -59.94M | -66.29M | -66.36M | -65M | -89.26M | -61.31M | -79.23M |
| Depreciation & Amortization | 2.87M | 3.06M | 3.1M | 3.11M | 3.1M | 3.23M | 3.21M | 3.64M | 3.56M | 3.48M | 3.57M | 3.64M |
| Stock-Based Compensation | 0 | 8.13M | 8.65M | 8.69M | 12.18M | 12.87M | 13.39M | 13.56M | 11.92M | 15.23M | 15.35M | 16.59M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.17M | 1.6M | 0 |
| Other Non-Cash Items | 8.45M | 226K | 108K | 2.36M | -176K | 1.86M | -15.61M | 2.32M | -1.94M | 75K | 147K | 1.5M |
| Working Capital Changes | 18.37M | -202K | -145K | -2.24M | -8.29M | 5.27M | 21.19M | -16.75M | -4.44M | -3.4M | -14.89M | -4.36M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 663K | 599K | -1.07M | -422K | -336K | 34K | -7.23M | 6.81M | -118K | -302K | -3.97M | -4.29M |
| Cash from Investing | -29.59M | 33.61M | 11.94M | 43.84M | 6.18M | 54.93M | -75.99M | 74.61M | 22.13M | 67.46M | -34.27M | 17.16M |
| Capital Expenditures | -9K | 0 | -243K | -44K | -99K | -257K | -429K | 0 | -8K | -181K | -12K | -288K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | 36.36% | -411.36% | 54.55% | 1309.09% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -67.64M | 34.26M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67.64M | -34.26M | 0 |
| Cash from Financing | 21.12M | 7.86M | 3.24M | 5.07M | 13.99M | 5.74M | 679K | 108.6M | 1.65M | 155K | 4.29M | 89.52M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 21.12M | 7.86M | 3.24M | 1.51M | 10M | 5.74M | 679K | 106.3M | 1.65M | 155K | 3.19M | 89.52M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 3.56M | 3.99M | 0 | 0 | 2.3M | 0 | 0 | 1.09M | 0 |
| Net Change in Cash | -21.38M | 13.87M | -14.52M | 9.88M | -32.76M | 23.98M | -119.43M | 119.63M | -32.12M | 13.91M | -85.51M | 44.83M |
| Free Cash Flow | -12.92M | -27.6M | -29.93M | -39.07M | -53.03M | -36.95M | -44.54M | -63.59M | -55.91M | -53.89M | -55.54M | -62.15M |
| FCF Margin % | - | - | - | - | - | - | - | - | -254122.73% | 122472.73% | -252463.64% | -282477.27% |
| FCF Growth % | 75.63% | 25.32% | 32.81% | 38.55% | 5.15% | 31.42% | 19.8% | -2.32% | 17.39% | 15.52% | -16.01% | -41.54% |
| FCF per Share | -0.05 | -0.13 | -0.13 | -0.18 | -0.25 | -0.18 | -0.21 | -0.33 | -0.33 | -0.32 | -0.33 | -0.42 |
| FCF Conversion (FCF/Net Income) | 0.30x | 0.71x | 0.72x | 0.77x | 0.89x | 0.61x | 0.67x | 0.96x | 0.86x | 0.60x | 0.89x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |